Nir Nimrodi

Nir joined Accellix as its Executive Chairman on June 2019. On January 2020, Nir was appointed as the company’s Chairman and Chief Executive Officer. Nir has 25 years of diverse international experience in both start-ups and large global businesses in the life science, pharmaceutical, and biotechnology industries. Prior to joining Accellix, Nir served as the Chief Business Officer of Intrexon Corporation, a leader in synthetic biology. Intrexon and its partners were among the pioneering companies in the field of immuno-oncology as well as several other gene therapy programs.

Prior to Intrexon, Nir held several executive roles at Life Technologies (now part of Thermo Fisher). While at Life, Nir served as Chief Executive Officer and Board Member of Life Technologies Israel, Head of Protein Technologies, as well as Vice President and General Manager of Food Safety and Animal Health. Prior to his seven years at Life Technologies, he was the CEO of Proneuron Biotechnologies and Mindsense Biosystems. Earlier in his career, Nir was a Director of Finance for Teva Pharmaceuticals.

Nir received his BA in Economics and his MBA from the Tel Aviv University.